Published in Proc Natl Acad Sci U S A on February 16, 2010
Role of IL-33 in inflammation and disease. J Inflamm (Lond) (2011) 2.06
Mast cells and inflammation. Biochim Biophys Acta (2010) 1.91
IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol (2011) 1.80
Regulation of mast cell responses in health and disease. Crit Rev Immunol (2011) 1.50
Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A (2013) 1.47
The ion channel TRPA1 is required for chronic itch. J Neurosci (2013) 1.41
Dynamic role of epithelium-derived cytokines in asthma. Clin Immunol (2012) 1.14
IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol (2014) 1.08
Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol (2013) 1.08
Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Proc Natl Acad Sci U S A (2012) 1.05
Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol (2011) 1.03
Focal brain inflammation and autism. J Neuroinflammation (2013) 1.03
Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol (2011) 1.03
Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs (2010) 1.02
Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol (2011) 1.02
Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol (2011) 1.01
Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One (2013) 0.99
Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci (2015) 0.99
Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies. Front Immunol (2013) 0.91
Mast Cells Respond to Cell Injury through the Recognition of IL-33. Front Immunol (2012) 0.91
Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One (2012) 0.90
Mast cell biology: introduction and overview. Adv Exp Med Biol (2011) 0.89
Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol (2012) 0.88
Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol (2013) 0.88
IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One (2012) 0.88
IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. Eur J Dermatol (2010) 0.88
IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy (2015) 0.87
Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis (2014) 0.86
IL-33 induces a hyporesponsive phenotype in human and mouse mast cells. J Immunol (2012) 0.85
Fibromyalgia Syndrome in Need of Effective Treatments. J Pharmacol Exp Ther (2015) 0.83
The novel cytokine interleukin-33 activates acinar cell proinflammatory pathways and induces acute pancreatic inflammation in mice. PLoS One (2013) 0.83
Biomarkers of An Autoimmune Skin Disease-Psoriasis. Genomics Proteomics Bioinformatics (2015) 0.82
Stress triggers coronary mast cells leading to cardiac events. Ann Allergy Asthma Immunol (2013) 0.80
Do mast cells link obesity and asthma? Allergy (2012) 0.80
Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells. Br J Dermatol (2012) 0.80
Mast Cells Regulate Wound Healing in Diabetes. Diabetes (2016) 0.79
Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharmacol (2011) 0.78
A candidate gene approach identifies an IL33 genetic variant as a novel genetic risk factor for GCA. PLoS One (2014) 0.78
Activation of tachykinin, neurokinin 3 receptors affects chromatin structure and gene expression by means of histone acetylation. Peptides (2012) 0.77
Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor. Clin Exp Immunol (2012) 0.77
[New aspects on the pathogenesis of psoriatic arthritis]. Z Rheumatol (2013) 0.77
Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators. PLoS One (2015) 0.77
Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells. J Pharmacol Exp Ther (2016) 0.76
Sphingosine-1-Phosphate/Sphingosine-1-Phosphate Receptor 2 Axis Can Promote Mouse and Human Primary Mast Cell Angiogenic Potential through Upregulation of Vascular Endothelial Growth Factor-A and Matrix Metalloproteinase-2. Mediators Inflamm (2016) 0.75
CD57 expression and cytokine production by T cells in lesional and unaffected skin from patients with psoriasis. PLoS One (2013) 0.75
Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma. Oncotarget (2016) 0.75
Are Mast Cells MASTers in Cancer? Front Immunol (2017) 0.75
Genitourinary mast cells and survival. Transl Androl Urol (2015) 0.75
Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques. Exp Ther Med (2015) 0.75
Nerve growth factor: a neuroimmune crosstalk mediator for all seasons. Immunology (2017) 0.75
Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med (Lausanne) (2017) 0.75
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell (1994) 16.30
The stress-activated protein kinase subfamily of c-Jun kinases. Nature (1994) 11.45
Psoriasis. N Engl J Med (2009) 8.80
Psoriasis. N Engl J Med (2005) 8.56
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (1991) 7.22
The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One (2008) 4.52
Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med (2005) 3.31
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins). J Biol Chem (1988) 2.45
IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol (2007) 2.38
IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest (2007) 2.37
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine (2007) 2.33
G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci (1990) 2.32
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
The role of substance P in inflammatory disease. J Cell Physiol (2004) 2.19
Retracted The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A (2009) 2.15
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood (2003) 2.03
Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol (2004) 1.98
Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol (2003) 1.79
Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology (1998) 1.71
Further exploring the brain-skin connection: stress worsens dermatitis via substance P-dependent neurogenic inflammation in mice. J Invest Dermatol (2007) 1.67
Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol (2005) 1.58
A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum. Proc Natl Acad Sci U S A (1994) 1.53
Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol (2009) 1.49
The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol (1994) 1.45
Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett (1990) 1.37
Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin (2005) 1.36
Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis (2001) 1.36
Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun (2006) 1.33
Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol (1999) 1.31
Substance P induces granulocyte infiltration through degranulation of mast cells. J Immunol (1989) 1.31
Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol (2005) 1.31
Stress, symmetry, and psoriasis: possible role of neuropeptides. J Am Acad Dermatol (1986) 1.30
IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res (2009) 1.27
Activation of rat peritoneal mast cells by substance P and mastoparan. J Pharmacol Exp Ther (1989) 1.23
G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides (2002) 1.19
Electron microscopical evidence for a direct contact between nerve fibres and mast cells. Acta Derm Venereol (1981) 1.15
Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J (2002) 1.13
Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol (1999) 1.12
Multiple signaling pathways for the activation of JNK in mast cells: involvement of Bruton's tyrosine kinase, protein kinase C, and JNK kinases, SEK1 and MKK7. J Immunol (1998) 1.12
The role of neuropeptides in psoriasis. Br J Dermatol (2006) 1.12
Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res (2007) 1.11
Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood (1999) 1.07
Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. Brain Behav Immun (2005) 1.04
Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. J Biomed Sci (2005) 1.02
Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol (2002) 0.97
L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol (1996) 0.96
Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol (1998) 0.95
VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol (2006) 0.94
Endogenous histamine excites neurones in the guinea-pig superior cervical ganglion in vitro. J Physiol (1989) 0.91
Antigen activation of mitogen-activated protein kinase in mast cells through protein kinase C-dependent and independent pathways. J Immunol (1997) 0.91
Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res (1995) 0.91
Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res (1993) 0.91
Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am (2006) 0.91
Role of substance P in stress-derived degranulation of dermal mast cells in mice. J Dermatol Sci (2006) 0.90
Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res (1997) 0.89
Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol (2007) 0.88
Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom (1993) 0.88
Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol (1996) 0.87
Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol (2004) 0.86
Association of psychic stress with clinical severity and symptoms of psoriatic patients. Acta Derm Venereol (1996) 0.86
Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol (2006) 0.86
Mast cells in psoriasis. Dermatology (1996) 0.85
NK-1 antagonist CP99994 inhibits stress-induced mast cell degranulation in rats. Clin Exp Dermatol (2004) 0.84
Substance P activates p38 mitogen-activated protein kinase to promote IL-6 induction in human dental pulp fibroblasts. Connect Tissue Res (2005) 0.84
Substance P: an historical perspective. Neuropeptides (2000) 0.84
Vascular endothelial growth factor 121 is the predominant isoform in psoriatic scales. Exp Dermatol (2005) 0.82
Presence of NK1 receptors on a mucosal-like mast cell line, RBL-2H3 cells. Can J Physiol Pharmacol (1998) 0.82
Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res (2003) 0.82
Neuropeptides and general neuronal marker in psoriasis--an immunohistochemical study. Clin Exp Dermatol (1995) 0.82
Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis. Anal Quant Cytol Histol (2007) 0.80
Expression of substance P receptors in normal and psoriatic skin. Pathobiology (1999) 0.80
The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. J Biol Regul Homeost Agents (2009) 0.79
Substance P can stimulate prostaglandin D2 and leukotriene C4 generation without granule exocytosis in murine mast cells. Eur J Pharmacol (2004) 0.78
The skin and the gut in psoriasis: the number of mast cells and CD3+ lymphocytes is increased in non-involved skin and correlated to the number of intraepithelial lymphocytes and mast cells in the duodenum. Acta Derm Venereol (1997) 0.78
Studies of the intracellular Ca2+ levels in human adult skin mast cells activated by the ligand for the human c-kit receptor and anti-IgE. Biochem Pharmacol (1994) 0.76
Pityriasis rosea-like eruption associated with lamotrigine. J Am Acad Dermatol (2013) 2.59
Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev (2007) 1.94
Mast cells and inflammation. Biochim Biophys Acta (2010) 1.91
Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol (2004) 1.79
IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett (2003) 1.76
A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis (2006) 1.69
The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology (2007) 1.67
Diet-induced obesity in mice causes changes in immune responses and bone loss manifested by bacterial challenge. Proc Natl Acad Sci U S A (2007) 1.67
A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv (2011) 1.58
High levels of intrauterine corticotropin-releasing hormone, urocortin, tryptase, and interleukin-8 in spontaneous abortions. Endocrinology (2003) 1.52
Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci (2004) 1.50
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. J Clin Psychopharmacol (2005) 1.49
Impact of stress and mast cells on brain metastases. J Neuroimmunol (2008) 1.46
Corticotropin-releasing hormone-receptor 2 is required for acute stress-induced bladder vascular permeability and release of vascular endothelial growth factor. BJU Int (2010) 1.46
Acute stress-induced seizures and loss of consciousness in a ten-year-old boy with cutaneous mastocytosis. J Clin Psychopharmacol (2002) 1.45
Chronic fatigue syndrome, mast cells, and tricyclic antidepressants. J Clin Psychopharmacol (2005) 1.44
LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: Evidence for LITAF-dependent LPS signaling pathways. Proc Natl Acad Sci U S A (2006) 1.40
Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci (2006) 1.31
Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol (2005) 1.31
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol (2010) 1.27
Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol (2004) 1.14
TSC1/2 tumour suppressor complex maintains Drosophila germline stem cells by preventing differentiation. Development (2010) 1.13
IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol (2003) 1.11
Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. J Clin Psychopharmacol (2007) 1.09
Serotonin-selective reuptake inhibitors and nonsteroidal anti-inflammatory drugs--important considerations of adverse interactions especially for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Psychopharmacol (2011) 1.09
Spectrum of mast cell activation disorders. Expert Rev Clin Immunol (2014) 1.08
Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci (2004) 1.07
Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res (2010) 1.06
A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol (2010) 1.04
Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation (2010) 1.04
Focal brain inflammation and autism. J Neuroinflammation (2013) 1.03
Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol (2011) 1.03
Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol (2011) 1.02
Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation (2010) 1.01
Role of mast cells in tumor growth. Ann Clin Lab Sci (2007) 1.01
Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res (2009) 0.99
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res (2012) 0.97
Neuro-inflammation, blood-brain barrier, seizures and autism. J Neuroinflammation (2011) 0.97
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol (2004) 0.96
Mast cells in allergic and inflammatory diseases. Curr Pharm Des (2012) 0.95
Mast cell activation and autism. Biochim Biophys Acta (2010) 0.95
Autism: an emerging 'neuroimmune disorder' in search of therapy. Expert Opin Pharmacother (2009) 0.95
Mercury induces inflammatory mediator release from human mast cells. J Neuroinflammation (2010) 0.94
Perinatal stress, brain inflammation and risk of autism-review and proposal. BMC Pediatr (2012) 0.94
Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos (2010) 0.94
Inducible nitric oxide synthase and heme oxygenase-1 in rat heart: direct effect of chronic exposure to hypoxia. Ann Clin Lab Sci (2003) 0.93
Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci (2008) 0.92
Novel therapeutic targets for autism. Trends Pharmacol Sci (2008) 0.92
Skin corticotropin-releasing hormone receptor expression in psoriasis. J Invest Dermatol (2007) 0.92
Contribution of stress to asthma worsening through mast cell activation. Ann Allergy Asthma Immunol (2012) 0.91
Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother (2002) 0.91
Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One (2012) 0.90
Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann Clin Lab Sci (2005) 0.90
Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol (2006) 0.90
Determination of dopamine, serotonin, and their metabolites in pediatric cerebrospinal fluid by isocratic high performance liquid chromatography coupled with electrochemical detection. Biomed Chromatogr (2010) 0.89
Tumor development in three patients with Noonan syndrome. Eur J Pediatr (2007) 0.88
IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One (2012) 0.88
Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice. Neurochem Res (2012) 0.88
Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol (2012) 0.88
Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One (2012) 0.88
Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci (2011) 0.88
Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther (2008) 0.88